Myelodysplastic syndromes (MDS) include a heterogenous group of clonal hematopoietic neoplasms characterized by dysplastic morphologic changes in one or more hematopoietic lineages in the bone marrow ...

Myelodysplastic neoplasms (MDS) are a diverse set of clonal myeloid neoplasms with dysregulated hematopoiesis, causing cytopenia and dysplastic hematopoietic cells. MDS is marked by recurrent ...

Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, spoke on current methods of classification and stratification for myelodysplastic ...

After a brief introduction, medical experts discuss advances in MDS classification and molecular understanding. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the ...

Incorporating Novel Targeted and Immunotherapeutic Agents in the Treatment of B-Cell Lymphomas Myelodysplastic syndrome (MDS) classification currently relies mainly on its morphologic features and ...

Somatic MDS mutations occur in five major categories, including RNA splicing, DNA methylation, activated cell signaling, myeloid transcription factors, and chromatin modifiers. Although many MDS cases ...

—Classifying myelodysplastic syndrome and secondary acute myeloid leukemia by genetic mutations rather than strictly by blast count may allow more patients to be eligible for AML and MDS clinical ...

Myelodysplastic syndrome (MDS) is a puzzling, life-threatening set of disorders for which there are no easy cures or quick remedies. Symptoms can range from weakness and excessive bruising to ...